Department of Clinical Microbiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Department of Health Policy, London School of Economics and Political Science, London WC2A 2AE, UK.
J Antimicrob Chemother. 2024 Feb 1;79(2):207-210. doi: 10.1093/jac/dkad393.
In Summer 2023, the World Health Organisation (WHO) and the Food and Agriculture Organization of the United Nations (FAO)-United Nations Environment Programme (UNEP) WHO-World Organisation for Animal Health (OIE) Quadripartite published two separate research agendas on antimicrobial resistance (AMR). While the publication of these research agendas on AMR creates a significant opportunity to align research priorities internationally, we emphasize a number of limitations. Firstly, the production of two separate AMR research agendas, in human health and One Health, rather than one integrated research agenda, risks the continued deprioritization of the One Health agenda. Furthermore, neither research agenda addressed the need to study the relationship between climate change and AMR despite growing evidence to suggest this may be significant. Finally, there are also missed opportunities in directing the study of appropriate treatment regimens and in clarifying the overall most resource-efficient path to combatting AMR. Moving forward, the international research agenda for AMR needs to be continually redefined in an inclusive, transparent and independent manner. This could be the task of the proposed, but so far not realized, Independent Panel on Evidence for Action against AMR.
2023 年夏季，世界卫生组织（世卫组织）和联合国粮食及农业组织（粮农组织）-联合国环境规划署（环境署）-世界动物卫生组织（OIE）四方发布了两份关于抗微生物药物耐药性（AMR）的单独研究议程。虽然发布这些 AMR 研究议程为国际上协调研究重点提供了一个重要机会，但我们强调了一些限制。首先，在人类健康和“同一健康”领域分别制定两份 AMR 研究议程，而不是一份综合研究议程，有可能继续使“同一健康”议程处于次要地位。此外，两份研究议程都没有解决研究气候变化与 AMR 之间关系的必要性，尽管越来越多的证据表明这可能很重要。最后，在指导适当治疗方案的研究以及澄清应对 AMR 的总体最具资源效率的途径方面，也存在错失的机会。展望未来，需要以包容、透明和独立的方式不断重新定义 AMR 的国际研究议程。这可能是拟议的、但迄今尚未实现的抗微生物药物耐药性行动独立小组的任务。
